Healthcare
Elicio Therapeutics, Inc.(ELTX)
Live Price
Offline$4.71
+70.65% today
1Y Change
-40.38%
Window
Jun 26, 2025 โ Jun 17, 2026
- Market Cap
- $200.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +39.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elicio Therapeutics, Inc. (ELTX) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $4.71 and down 40.4% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +39.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +39.3%, free cash flow +0.5% with operating margin 0.0% and ROIC -201.0%. Stock Foundry combines ELTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +39.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +7.1% | -13.1% | +35.5% |
2026 Mar 12, 2026 | -4.3% | +11.9% | +9.9% | -6.9% |
2025 Nov 13, 2025 | +3.2% | -2.2% | -12.3% | -10.2% |
Benchmark Edge
ELTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELTX Max Drawdown
-81.41%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELTX and SPY.
Company Overview
Elicio Therapeutics, Inc.
NASDAQ Global Market
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
- Leadership
- Robert T. Connelly
- IPO Date
- Feb 5, 2021
- Employees
- 32
- Street Address
- 451 D Street
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857-209-0050
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 99.1
Growth
- Revenue
- 0.0%
- EPS
- +39.3%
- Free Cash Flow
- +0.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -977.7%
- ROIC
- -201.0%
Balance Sheet
- Debt/Equity
- 3.12
- Current Ratio
- 2.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.